Abstract
Proteins and peptides have been used to deliver radioactivity to target cells for both diagnostic and therapeutic purposes. However, high and persistent localization of radioactivity was observed in the liver or kidney, which reduces diagnostic accuracy and compromises therapeutic effectiveness. Thus, radiolabeled proteins and peptides would become much more useful in both targeted imaging and radiotherapy if the undesirable radioactivity localization can be diminished. As a means to reduce the undesirable radioactivity, interposition of a metabolizable linkage or other chemical modification is performed.
In this paper, strategies to alter pharmacokinetics of radiolabeled proteins and peptides are described.
